Cancer, Stem Cells, Tumor Initiating Cells, Melanoma, Neural Crest, Tumor Heterogeneity

Ngo M, Han A, Lakatos A, Debashis S, Hachey SJ, Weiskopf K, Beck A, Weissman IL, Boiko AD. Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis Cell Reports, 2016, Jul 28, doi:10.1016/j.celrep.2016.07.004 Hachey SJ, Boiko AD. Therapeutic Implications of Melanoma Heterogeneity. Exp Dermatol. 2016 Apr 8. [Epub ahead of print] Dimov IK, Boiko AD. Profiling Melanoma Heterogeneity Using Microwell RNA Cytometry. Methods Mol Biol. 2016 Apr 16. [Epub ahead of print] Boiko AD Isolation of Melanoma Tumor Initiating Cells from Surgical Tissues Methods Mol Biol. 2013;961:253-9. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, Broome-Powell M, Giaccia AJ. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1931-6. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010 Jul 1;466(7302):133-7. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 2006 Jan 15;20(2):236-52. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7112-7. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV, Kiyokawa H. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 2002 Nov 15;16(22):2923-34. Axenovich SA, Kazarov AR, Boiko AD, Armin G, Roninson IB, Gudkov AV. Altered expression of ubiquitous kinesin heavy chain results in resistance to etoposide and hypersensitivity to colchicine: mapping of the domain associated with drug response. Cancer Res. 1998 Aug 1;58(15):3423-8.